admin

Blue-chip stocks are shares of well-established, stable firms that pay dividends in most cases. It’s that combination of stability and dividend income that makes them so attractive. So, investors should scoop them up when they find blue-chip stocks that are undervalued.  One of the other benefits of investing in blue-chip stocks is that they tend
0 Comments
It’s important to keep a look out for dividend stocks to sell in your portfolio. I’ll always believe that there’s nothing better than a quality dividend stock, one that not only provides a decent return but also has a solid dividend history to reward shareholders. That’s why I will also be disappointed in a poor
0 Comments
In my previous Palantir (NYSE:PLTR) article, I expressed why investors should be cautious when investing in the AI-driven stock. PLTR stock rose nearly 140% this year due to strong earnings and AI growth. However, concerns about overvaluation loom large over this meme-stock-turned-AI-champion. My view on this company remains the same. Indeed, Palantir posted its third
0 Comments
While penny stocks promise substantial potential gains, the reality is that sub-$5 stocks are among the riskiest investments. Their low price often reflects underlying issues like weak business models, high debt, dwindling market share, and uncertain prospects. True, each new month brings fresh investment possibilities where significant capital isn’t required. Penny stocks offer opportunities with
0 Comments
Small-cap stocks are a perennial favorite among retail investors. On average, small-cap stocks (as a category) outperform the overall market over a long enough period. Since analysts began breaking down market capitalization by category in the US, small-cap stocks returned more than 17% annually on average.  However, the upside potential is coupled with greater downside
0 Comments
While the health innovation space presents wild risks, you could potentially swing the odds in your favor with strong buy biotech stocks. Specifically, these ideas represent publicly traded biotechnology firms that enjoy the highest possible consensus rating among Wall Street analysts. So, what’s the key advantage regarding these analyst-endorsed biotech stocks to buy? Fundamentally, you’re
0 Comments
The broader market indexes would have you believe we’re in the midst of a steady, long-term recovery. But those of us trading individual stocks, especially more speculative penny and growth names, know the truth. This market is still quite choppy. We’ve already seen a handful of scary downturns this year. While they don’t look too
0 Comments
Apparently, electric vehicle (EV) manufacturer Mullen Automotive (NASDAQ:MULN) is expanding its business operations into a new area — again. The MULN stock bulls might celebrate this, but consider the big picture. All in all, the risk-to-reward balance still doesn’t favor Mullen Automotive and its investors. I’ll admit, there may be a news item or two
0 Comments